https://www.businesswire.com/news/home/20180613006329/en/

MELBOURNE, Australia & SAN FRANCISCO--(BUSINESS WIRE)--Jun 13, 2018--Prana Biotechnology Ltd (ASX PBT: NASDAQ PRAN) is pleased to announce it has received ethics committee approval and has commenced recruitment for its Phase I Clinical trial evaluating the safety, tolerability and pharmacokinetics of the Company’s lead drug candidate, PBT434, in healthy volunteers.

PBT434 is the first of a new generation of small molecules designed to inhibit the aggregation of alpha(α)-synuclein and tau, vital intracellular proteins that are implicated in neurodegenerative diseases such as Parkinson’s disease and atypical parkinsonism. PBT434 has been shown to reduce the abnormal accumulation of these proteins in animal models of disease by restoring normal iron balance in the brain.